Juneja Riddhima, Khan Taskin, Gupta Vishnu Swarup, Chaudhary Niharika
Department of Ophthalmology, HAH Centenary Hospital, Hamdard Institute of Medical Sciences and Research, New Delhi, 110062, India.
Int Ophthalmol. 2025 Jun 12;45(1):240. doi: 10.1007/s10792-025-03590-7.
To compare the intraocular pressure (IOP) lowering effect and safety of topical netarsudil 0.02% once daily with topical ripasudil 0.4% twice daily in primary open angle glaucoma (POAG) patients.
A prospective, comparative, randomized study conducted on 140 eyes of patients diagnosed to have POAG, in a tertiary care hospital of Northern India. Patients divided into groups, A and B in a 1:1 ratio and were treated with ripasudil 0.4% or netarsudil 0.02% respectively and followed up. The mean diurnal IOP noted at 3rd week and 3rd month comparing it from baseline values, with their side effects.
At 3rd month, meandiurnal IOP for ripasudil 0.4% group ranged from 19.22 to 20.69 mmHg whereas for netarsudil group it was 17.11-18.47 mmHg, an intergroup statistically significant difference in IOP of 2.3 mmHg (p < 0.0001) noted. At 3 month the difference from baseline was 2.77 mmHg (p = 0.048) for ripasudil and 4.64 mmHg (p = 0.001) for netarsudil. At the end of 3 months the adverse events were seen less in group B than group A (59.8% and 66.7% respectively. Eye irritation followed by conjunctival hyperemia was seen. Overall incidence of adverse events was 32.9% and 44.3% for topical netarsudil and ripasudil respectively.
Topical netarsudil 0.02% once daily was well tolerated with fewer side effects and in reducing IOP than topical ripasudil 0.4% twice daily dosing in POAG patients. Netarsudil 0.02% once daily may be considered an important option for the IOP control in POAG.
比较原发性开角型青光眼（POAG）患者中，每日一次局部使用0.02%奈他地尔与每日两次局部使用0.4%利马前列素降低眼压（IOP）的效果及安全性。
在印度北部一家三级护理医院，对140例诊断为POAG的患者的眼睛进行了一项前瞻性、对比性、随机研究。患者按1:1比例分为A组和B组，分别接受0.4%利马前列素或0.02%奈他地尔治疗并进行随访。在第3周和第3个月记录平均日间眼压，并与基线值进行比较，同时观察其副作用。
在第3个月时，0.4%利马前列素组的平均日间眼压为19.22至20.69 mmHg，而奈他地尔组为17.11 - 18.47 mmHg，两组间眼压存在2.3 mmHg的统计学显著差异（p < 0.0001）。在3个月时，利马前列素组与基线的差异为2.77 mmHg（p = 0.048），奈他地尔组为4.64 mmHg（p = 0.001）。在3个月末，B组的不良事件比A组少（分别为59.8%和66.7%）。观察到眼部刺激，随后出现结膜充血。局部使用奈他地尔和利马前列素的不良事件总发生率分别为32.9%和44.3%。
在POAG患者中，每日一次局部使用0.02%奈他地尔耐受性良好，副作用较少，且在降低眼压方面优于每日两次局部使用0.4%利马前列素。每日一次使用0.02%奈他地尔可被视为POAG眼压控制的重要选择。
